Last reviewed · How we verify
aliskiren, eplerenon, telmisartan
At a glance
| Generic name | aliskiren, eplerenon, telmisartan |
|---|---|
| Sponsor | Medical University of Gdansk |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- The Effect of Various Types of the Renin-angiotensin-aldosterone System Blockade on Proteinuria (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aliskiren, eplerenon, telmisartan CI brief — competitive landscape report
- aliskiren, eplerenon, telmisartan updates RSS · CI watch RSS
- Medical University of Gdansk portfolio CI